NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty testing services to the worldwide nutraceuticals, biotechnology, cosmetics, and food and beverage industries. The company today announced the execution of a manufacturing, sales and distribution agreement with Canopy CBD Farms LLC (“CCF”), a Massachusetts licensed processor/manufacturer/distributor of hemp-derived CBD products and processing equipment. With a strong focus in the Massachusetts/New England hemp-derived CBD market and with hundreds of nationwide industry connections, CCF has assembled an aggressive distribution plan that anticipates nano-CBD product sales of nearly $6 million over the first 12-months post-release. “Our PBI team is incredibly excited as we now transition into production of UST-based products and what we believe will be impressive and highly profitable product revenues in late 2022, then accelerating into 2023 and beyond. Our team has demonstrated focus, commitment and resolve in completing the development of a world-class, patented method for processing hemp-derived CBD into the highest quality, commercial grade nanoemulsions available today,” said Kenneth F. Micciche, director of business development at PBI. “This achievement allows PBI to immediately begin to work with CCF to help them leverage their impressive industrial network and connections to dispensaries, eCommerce, and other channel partners, as they use the UST competitive advantage to drive revenue growth in this estimated $16.6 billion market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer